Ghrelin as radiation countermeasure: mechanism of its action - project description: this U01 project aims to elucidate a novel neuroenteric mechanism through which ghrelin confers intestinal…

Active Cooperative Agreement Awarded Last action

Award ID
U01AI186997
Recipient
Awarding agency
Obligated
$1,758,720

Award facts

Assistance listing
93.310 Trans-NIH Research Support
Completion date 38% complete
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Manhasset, NY 11030, USA

Award details come from USAspending.gov.

Description

Ghrelin as radiation countermeasure: mechanism of its action - project description: this U01 project aims to elucidate a novel neuroenteric mechanism through which ghrelin confers intestinal radioprotection, and to preclinically develop human ghrelin as a safe and effective mitigator for gastrointestinal acute radiation syndrome (GI-ARS). Ghrelin is a small peptide secreted by the stomach that readily crosses the blood-brain barrier. In our preliminary studies, ghrelin significantly improved the intestinal integrity and survival in the context of inflammatory enteropathy. After radiation injury, serum levels of ghrelin were markedly decreased, and ghrelin treatment significantly improved intestinal integrity, increased crypt depth, and doubled the survival rate. Interestingly, ghrelin's protective effects in radiation combined injury were abrogated by prior subdiaphragmatic vagotomy, indicating that ghrelin primarily acts in the central nervous system with its beneficial effects conveyed to the GUT through the vagus nerve. Next, we established ghrelin's dose-response to improve survival after partial body irradiation, a better model to study severe GI-ARS. After radiation exposure, dying intestinal stem cells (LGR5+ cells) must be replenished by otherwise quiescent clusterin (CLU+) revival stem cells. We demonstrated the feasibility of evaluating LGR5+ stem cells as the target on ghrelin's neuroenteric regulation, and showed that both LGR5+ stem cells and CLU+ revival stem cells express cholinergic receptors. As such, we hypothesize that ghrelin mitigates radiation injury via the efferent vagus nerve and the enteric nervous system to promote intestinal crypt LGR5+ stem cell recovery from CLU+ revival stem cells. Human ghrelin has been evaluated in phase i clinical trials with an excellent safety profile. Moreover, IT can be synthesized in large quantities for mass emergency needs. Based on our positive preliminary results, we also hypothesize that human ghrelin can be further developed as an effective GI-ARS mitigator. In this proposal, we will elucidate ghrelin's neuroenteric mechanism, its effects on LGR5+ stem cells and CLU+ revival stem cells, and its efficacy, PK, and safety pharmacology as a mitigator for GI-ARS. These studies shall characterize human ghrelin's novel mechanism of action and develop IT as a safe and effective countermeasure for victims of major radiation exposure.

Transactions

Action Obligated Date
Amendment $586,240
Amendment $586,240
Original award $586,240

Quick answers

Who received award U01AI186997?

U01AI186997 was awarded to The Feinstein Institutes For Medical Research by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 5, 2024.

How much is award U01AI186997 worth?

$1,758,720 has been obligated on U01AI186997.

Which agency awarded U01AI186997?

National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded U01AI186997, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award